- Remove All
- Your shopping cart is currently empty
- A unique collection of 500 compounds targeting MAPK signaling for drug discovery in MAPK related diseases;
- Bioactivity and safety confirmed by pre-clinical research and clinical trials, and some of them are approved by FDA;
- Targets include ERK, JNK, MEK, p38, MAPK, Raf, RSK, MNK, etc;
- Detailed compound information with structure, target, activity, IC50 value, and biological activity description;
- Structurally diverse, medicinally active, and cell permeable;
- NMR and HPLC validated to ensure high purity and quality;